ANI Pharmaceuticals vs Ascendis Pharma A/S
ANIP and ASND side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ANIP and ASND compare
Ascendis Pharma A/S grew revenue faster over the last twelve months (113% versus 30.9% for ANI Pharmaceuticals).
Ascendis Pharma A/S keeps more of each dollar of sales as profit, with a net margin of 70.8% compared with 11.1% at ANI Pharmaceuticals.
ANI Pharmaceuticals scores higher on the StockData Score (13 against 7 for Ascendis Pharma A/S), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ANIP | ASND |
|---|---|---|
| Size and price | ||
| Market cap | $1.7B | – |
| Share price | $72.00 | $251.27 |
| Change, 1 year | −21.9% | 22.1% |
| Change, 5 years | 43.9% | 56.4% |
| Beta (5Y) | 0.59 | 0.77 |
| Employees | 970 | 879 |
| StockData Score | ||
| Total score | 13 (better) | 7 |
| Valuation score | 4 (better) | 0 |
| Growth score | 2 | 3 (better) |
| Performance score | 4 (better) | 2 |
| Health score | 3 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 15.3× | – |
| P/S | 1.7× | – |
| P/B | 2.8× | – |
| EV/EBITDA | 6.8× | – |
| P/FCF | 9.6× | – |
| FCF yield | 10.5% | – |
| Fair value | $113.03 | – |
| Margin of safety | 36.3% | – |
| Growth | ||
| Revenue growth (TTM) | 30.9% | 113% (better) |
| Revenue growth, 5Y average | 33.5% | 153% (better) |
| Profitability | ||
| Gross margin | 60.4% | 91.3% (better) |
| Operating margin | 15.4% | 25.4% (better) |
| Net margin | 11.1% | 70.8% (better) |
| FCF margin | 17.7% | – |
| Return on equity | 21.0% | – |
| Return on invested capital | 21.3% | – |
| Financial health | ||
| Debt / equity | 0.50 | – |
| Net debt / EBITDA | −0.25 | −1.61 |
| Interest coverage | 4.8× (better) | 1.3× |
| Current ratio | 2.91 | 2.99 (better) |
| Altman Z-score | 2.56 | – |
| Piotroski F-score | 7 (better) | 5 |
| Dividends and buybacks | ||
| Payout ratio | 0.32% | – |
| Buyback yield | 1.3% | – |
| Shareholder yield | 1.3% | – |
| Ownership | ||
| Held by institutions | 100% | 108% |
| Held by insiders | 12.3% | 0.83% |
| Insider net buying, 12 months | −$15.0M | −$4.7M (better) |
| Short interest, % of float | 17.3% | – |
Go deeper
- ANIP stock overview
- ANIP income statement
- ANIP valuation and score
- ASND stock overview
- ASND income statement
- ASND valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.